Published in Drug Law Weekly, March 6th, 2007
The notes will bear interest at a rate of 7.75% per annum and be convertible into shares of Vion's common stock at an initial conversion rate of 520.833 shares of common stock per $1,000 principal amount of notes, subject to adjustment (equivalent to an initial conversion price of $1.92 per share, representing a conversion premium of 20% to the last reported sale price of $1.60 per share on February 13, 2007). Subject...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.